• Scientists make leukaemia treatment discovery
    Leukaemia drug discovery could prevent some patients having toxic treatments

News & Views

Scientists make leukaemia treatment discovery

May 17 2011

A study of mice is the first step to relieve some acute myeloid leukaemia (AML) patients from toxic treatments and increase the research into therapeutic treatments.

Scientists at the Wake Forest Baptist Medical Center found during the treatment of mice with leukaemia that those with a FLT3-ITD mutation, the most common type and associated with poor prognosis, that certain types of drugs frequently used in treatment protect the cancer cells.

Dr Timothy S. Pardee, an assistant professor of hematology and oncology and lead author of the study, told the journal Experimental Hematology that the FLT3-ITD mutation seems to make cells more sensitive to the impact of cytarabine, while making it almost immune to a combination of cytarabine and doxorubicin.

Scientists found that mice with the FLT3-ITD mutation succumbed to cancer at the same rate as those which were untreated.

"It's almost like the doxorubicin is protecting the cancer cells somewhat from the impact of the cytarabine, which is trying to kill the cell," Dr Pardee said.

He explained that while more research is needed, the study could prevent many leukaemia patients from having to undergo the extremely toxic doxorubicin treatment.  

Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events